Emerging evidence of the benefit of antibody-drug conjugates in diffuse large B-cell lymphoma continues to make a strong case for the agents to be used in earlier lines of therapy.
January 2026
XmAb819 shows promising antitumor activity and manageable safety in clear cell renal cell carcinoma patients, highlighting its potential in future therapies.
Immunotherapy shows significant survival benefits for metastatic chromophobe renal cell carcinoma patients with sarcomatoid features, suggesting a potential predictive biomarker.
Vorasidenib significantly reduces tumor growth rates in grade 2 glioma patients, improving progression-free survival and time to next intervention.
A phase 1 study reveals that sequential CR7-GD2 CAR T-cell therapy administration is better tolerated in pediatric CNS tumor patients than concurrent methods.
A study reveals cabozantinib plus nivolumab shows a 71% response rate in fumarate hydratase-deficient renal cell carcinoma, promising survival outcomes.